-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Medline, Raises Price Target to $49

Benzinga·11/06/2026 00:31:13
Listen to the news
UBS analyst Kevin Caliendo maintains Medline (NASDAQ:MDLN) with a Buy and raises the price target from $43 to $49.